HC Wainwright Issues Negative Forecast for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD) – HC Wainwright dropped their Q3 2026 EPS estimates for PolyPid in a report released on Wednesday, August 12th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.41) per share for the quarter, down from their prior forecast of ($0.40). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.44) EPS.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03.

PYPD has been the subject of several other research reports. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Craig Hallum set a $12.00 target price on PolyPid in a report on Wednesday, July 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.33.

PolyPid Price Performance

Shares of PYPD stock opened at $4.78 on Friday. The company has a market cap of $91.20 million, a price-to-earnings ratio of -3.23 and a beta of 1.41. The stock’s fifty day moving average price is $4.73 and its 200 day moving average price is $4.57. PolyPid has a 1-year low of $3.06 and a 1-year high of $5.73.

Hedge Funds Weigh In On PolyPid

Large investors have recently bought and sold shares of the business. AIGH Capital Management LLC purchased a new position in shares of PolyPid in the 2nd quarter valued at about $7,644,000. ADAR1 Capital Management LLC purchased a new stake in shares of PolyPid in the fourth quarter valued at about $451,000. Renaissance Technologies LLC purchased a new position in shares of PolyPid in the 1st quarter valued at approximately $81,000. Jane Street Group LLC acquired a new position in PolyPid in the 4th quarter valued at $66,000. Finally, XTX Topco Ltd raised its holdings in PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares in the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.